Interestingly, efforts to develop small molecule inhibitors of GCPII to treat brain disorders of hyperglutamatergic pathogenesis led to the discovery of their application outside of the nervous system, most prominently as imaging and therapeutic agents in prostate cancers [10]. Here, FOLH1 is linked to prostate carcinoma.